# Semaglutide Carbon Footprint: A UK Lifetime Emissions Model | This GLP A UK disease model gave semaglutide lower lifetime carbon emissions in two groups and higher in a third (14,700 against 14,444 kg CO2e) because patients lived longer. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-lifetime-carbon-emissions Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Semaglutide Carbon Footprint: A UK Lifetime Emissions Model A disease model found semaglutide lowered lifetime carbon emissions in two UK populations and raised them in a third, because the people in it survived longer. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Modeled change in lifetime carbon emissions · BMI 30+, or 27+ with a complication · 1.8% lower · BMI 27+ with a complication · 1.8% lower · BMI 27+ with heart disease · about 1.8% higher · The third group lived longer. 14,700 against 14,444 kg CO2e. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A Markov model estimated the lifetime carbon footprint of semaglutide against diet and exercise alone in the UK. - In two populations, modeled emissions fell by 1.8%, alongside 0.30 and 0.25 extra life-years. - In the population with established heart disease, emissions rose: 14,700 against 14,444 kg CO2e. - The reason they rose is that people lived longer and were monitored more. - Every author is a Novo Nordisk employee, adviser, IQVIA employee, or works for a consultancy Novo has funded. Somebody had to ask this question eventually, because health systems buying at national scale now have emissions targets attached to their procurement, and a weekly injection manufactured, refrigerated and shipped for years is not a small object in that arithmetic. The answer the model returns is interesting mostly for the part that does not fit the conclusion, which is a pattern this site keeps meeting in [modeled evidence generally](https://thisglp.com/research/telehealth-glp1-program-trial). ## What was modeled A cohort state-transition model, fed with results from the STEP and SELECT trials, estimated per-patient emissions across a lifetime for semaglutide 2.4 mg added to diet and exercise, against diet and exercise on their own, in three UK populations. [\[1\]](https://thisglp.com/research/semaglutide-lifetime-carbon-emissions#ref-1) Nothing here was weighed or metered; every figure is an output of the model’s assumptions about how obesity-related complications would otherwise have unfolded. In the two populations defined by body mass index and complications, the drug came out ahead on everything the model tracked: 0.30 and 0.25 additional life-years, 0.51 and 0.46 additional quality-adjusted life-years, and lifetime emissions lower by 1.8%. The manufacturing footprint of the drug was more than offset by the complications the model expected it to prevent. ## The third population Among people with a body mass index over 27 and established cardiovascular disease, the clinical results were the best of the three — 0.56 additional life-years and 0.59 additional quality-adjusted life-years — and the carbon result went the other way, with modeled lifetime emissions of 14,700 kg CO2e against 14,444 for the comparator. The gap of 256 kilograms, about 1.8% higher, is this desk’s subtraction from the paper’s two published figures. The stated reason is longer survival and more monitoring. People who do not die of a heart attack go on consuming healthcare, and healthcare emits. What that reversal actually means It means the environmental result is a function of how the model prices survival, not a property of the drug, because any therapy that keeps people alive longer will add years of emissions to its own ledger — and a model that counts those years as a cost will find every life-extending treatment environmentally worse the better it works. The paper does not say that; it reports the reversal accurately and then concludes that semaglutide offers clinical and environmental benefits supporting the UK’s net-zero goals, which is true of two populations out of three and is [stated more broadly than the results support](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease). ## Who wrote it Two of the authors are employees and shareholders of Novo Nordisk, which makes semaglutide. One sits on the company’s Sustainability Advisory Council under contract. Five are employees of IQVIA, and one works for a health-economics consultancy that has received Novo Nordisk funding in the past three years. That is the entire author list, and the disclosure is published in full, which is the right way to do it. None of it makes the model wrong — a manufacturer usually holds the data nobody else has — but a reader deciding how much weight to give a favorable environmental conclusion is entitled to know that no independent party checked the assumptions that produced it. ## What it has to do with buying one Almost nothing, which is worth saying plainly on a site whose readers are paying for these drugs out of pocket. This paper argues to a health system deciding what to stock, and a life-year in a model is not a promise to any individual, for the same reason [a modeled clock is not a lifespan](https://thisglp.com/research/do-glp1-drugs-slow-aging). What it is good for is calibration. When a study arrives showing that a drug is good on an axis nobody was arguing about, the question to ask first is who needed that answer — the same question worth asking about [any ranking that flatters a seller](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming). ## Frequently asked Does semaglutide lower carbon emissions? In this model, in two of three populations, by 1.8% over a lifetime. In the third, people with established heart disease, modeled emissions rose from 14,444 to 14,700 kg CO2e. Why did emissions go up in one group? Because those patients lived longer and were monitored more. Any treatment that extends life adds years of healthcare emissions to its own account. Was this measured or estimated? Estimated. It is a cohort state-transition model fed with STEP and SELECT trial results. No emissions were metered. Who funded it? The author list consists of Novo Nordisk employees and shareholders, a contracted adviser to the company's sustainability council, IQVIA employees, and a consultant whose firm has received Novo Nordisk funding. All of it is disclosed in the paper. ## Sources 1. \[1\] Lund N, et al. (2026). Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling Approach PharmacoEconomics. [PMID 42722807](https://pubmed.ncbi.nlm.nih.gov/42722807/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)